drugset / Trial / NCT06656091
A Study of Simmitinib Versus Chemotherapy for Participants With Advanced Oesophageal Squamous Cell Carcinoma
RandomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the overall survival of simmitinib versus investigator's choice of chemotherapy for Participants with advanced or metastatic oesophageal squamous cell carcinoma who have disease progression after first-line standard therapy.
Timeline
- Start
- 2024-10-31
- Primary completion
- 2027-01-30
- Completion
- 2027-01-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Docetaxel | Small molecule | 75 mg/m2 | — |
| Comparator | Irinotecan | Small molecule | 180 mg/m2 | — |
| Subject | Simmitinib | Small molecule | 6 mg | — |